Oxcarbazepine: Difference between revisions
(renal hepatic dosing edits) |
(peds dosing) |
||
| Line 20: | Line 20: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
===Partial seizures=== | |||
====adjunct therapy==== | |||
*2-3 yo | |||
**Dose: 60 mg/kg/day PO divided bid; Start: 8-10 mg/kg/day PO divided bid up to 600 mg/day, incr. dose over 2-4wk; Max: 60 mg/kg/day | |||
**may start 16-20 mg/kg/day PO divided bid in pts <20 kg | |||
*4-16 yo, 20-29 kg | |||
**Dose: 600 mg PO bid; Start: 8-10 mg/kg/day PO divided bid up to 600 mg/day, incr. to target dose over 2wk | |||
*4-16 yo, >39 kg | |||
**Dose: 900 mg PO bid; Start: 8-10 mg/kg/day PO divided bid up to 600 mg/day, incr. to target dose over 2wk | |||
====monotherapy==== | |||
*4-16 yo, 20-24 kg | |||
**Dose: 300-450 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, incr. by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy | |||
**D/C concomitant anticonvulsants over 3-6wk | |||
*4-16 yo, 25-34 kg | |||
**Dose: 450-600 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, incr. by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy | |||
**D/C concomitant anticonvulsants over 3-6wk | |||
*4-16 yo, 35-44 kg | |||
**Dose: 450-750 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, incr. by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy | |||
** D/C concomitant anticonvulsants over 3-6wk | |||
*4-16 yo, 45-49 kg | |||
**Dose: 600-750 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, incr. by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy | |||
**D/C concomitant anticonvulsants over 3-6wk | |||
*4-16 yo, 50-59 kg | |||
**Dose: 600-900 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, incr. by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy | |||
**D/C concomitant anticonvulsants over 3-6wk | |||
*4-16 yo, 60-69 kg | |||
**Dose: 600-1050 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, incr. by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy | |||
**D/C concomitant anticonvulsants over 3-6wk | |||
*4-16 yo, >70 kg | |||
**Dose: 750-1050 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, incr. by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy | |||
**D/C concomitant anticonvulsants over 3-6wk | |||
==Special Populations== | ==Special Populations== | ||
Revision as of 23:38, 10 February 2016
Administration
- Type: anti epileptic
- Dosage Forms: 150,300,600; 300/5 mL
- Routes of Administration: PO
- Common Trade Names: Trileptal
Adult Dosing
Partial seizures
- adjunct tx: Dose: 600 mg PO bid; Start: 300 mg PO bid, incr. by up to 600 mg/day qwk; Max: 2400 mg/day;
- conversion to monotherapy: Dose: 1200 mg PO bid; Start: 300 mg PO bid, incr. by up to 600 mg/day qwk; Max: 2400 mg/day; D/C concomitant anticonvulsants over 3-6wk; taper dose gradually to D/C
- initial monotherapy: Dose: 600 mg PO bid; Start: 300 mg PO bid, incr. by 300 mg/day q3 days; Max: 2400 mg/day
Trigeminal neuralgia
- 450-1200 mg PO bid
- Start: 300 mg PO bid, may incr. by 600 mg/day qwk
Bipolar disorder
- 600-1200 mg PO bid
- Start: 300 mg PO bid, incr. by 300 mg/day q3 days or by 600 mg/day qwk
Pediatric Dosing
Partial seizures
adjunct therapy
- 2-3 yo
- Dose: 60 mg/kg/day PO divided bid; Start: 8-10 mg/kg/day PO divided bid up to 600 mg/day, incr. dose over 2-4wk; Max: 60 mg/kg/day
- may start 16-20 mg/kg/day PO divided bid in pts <20 kg
- 4-16 yo, 20-29 kg
- Dose: 600 mg PO bid; Start: 8-10 mg/kg/day PO divided bid up to 600 mg/day, incr. to target dose over 2wk
- 4-16 yo, >39 kg
- Dose: 900 mg PO bid; Start: 8-10 mg/kg/day PO divided bid up to 600 mg/day, incr. to target dose over 2wk
monotherapy
- 4-16 yo, 20-24 kg
- Dose: 300-450 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, incr. by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
- D/C concomitant anticonvulsants over 3-6wk
- 4-16 yo, 25-34 kg
- Dose: 450-600 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, incr. by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
- D/C concomitant anticonvulsants over 3-6wk
- 4-16 yo, 35-44 kg
- Dose: 450-750 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, incr. by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
- D/C concomitant anticonvulsants over 3-6wk
- 4-16 yo, 45-49 kg
- Dose: 600-750 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, incr. by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
- D/C concomitant anticonvulsants over 3-6wk
- 4-16 yo, 50-59 kg
- Dose: 600-900 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, incr. by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
- D/C concomitant anticonvulsants over 3-6wk
- 4-16 yo, 60-69 kg
- Dose: 600-1050 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, incr. by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
- D/C concomitant anticonvulsants over 3-6wk
- 4-16 yo, >70 kg
- Dose: 750-1050 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, incr. by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
- D/C concomitant anticonvulsants over 3-6wk
Special Populations
Renal Dosing
- Adult: CrCl <30: start 150 mg bid; HD/PD: no supplement; Info: titrate dose slowly until response
- Pediatric:
Hepatic Dosing
- Adult: mild-mod impairment: no adjustment; severe impairment: not defined
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
